Certificate in Cancer Immunotherapy

CP2_-_Copy.png

The Society for Immunotherapy of Cancer (SITC) is pleased to offer physicians and qualified healthcare providers the opportunity to earn a Certificate in Cancer Immunotherapy, supporting their knowledge and skills to provide effective and safe care for patients treated with cancer immunotherapy. Learners can expect to develop a comprehensive understanding of cancer immunotherapies, including checkpoint inhibitors, cell therapies and many others, as well as the management of side effects, allowing them to successfully implement immunotherapy in clinical practice.  

The Certificate in Cancer Immunotherapy consists of eight independent learning modules that can be stacked to earn the SITC Graduate in Cancer Immunotherapy (SITC-G) certificate. The SITC-G certificate identifies a healthcare provider as completing specialized training in cancer immunotherapy.  All modules are approved for CME, CNE, CPE and MOC credits, except where noted.

Learning Modules

SITC-G Certificate Track
Available only to those that fit the following parameters: Must be a treating physician (U.S. licensed MD / DO or global equivalent), or a practicing licensed NP, PA, PharmD or RPh degree holder involved in direct clinical services, or global equivalent.

Full Coursework Pricing: (includes all 8 modules and the final assessment)

SITC Member Price: $200.00
Non-Member Price: $250.00

To receive your SITC-G certificate, you must complete the 8 modules of course work below and successfully pass the final assessment. The final assessment consists of 80 multiple choice questions that test on all 8 modules of content. To pass the final assessment, you must receive a grade of 80% or above. You will have 3 attempts and 65 minutes to complete the test in full. If you do not successfully complete the final assessment in those parameters, SITC will require you to go through the modules of content again - please email education@sitcancer.org to have the content reset for you.

Full Certificate Course Program Access

  • Module 1: Basic Immunology Concepts, Updated Version Available Now (As of 10/14/2022*
  • Module 2: Basic Cancer Immunotherapy Concepts, Updated Version Available Now (As of 11/14/2022*
  • Module 3: Immune Checkpoint Blockade, Updated Version Available Now (As of 03/20/2023*
  • Module 4: Managing Immune Checkpoint Inhibitor Adverse Events
  • Module 5: Other Approaches (Cytokines, Vaccines and Immune Cell Engagers)
  • Module 6: Oncolytic Viruses and Intralesional Therapy, Updated Version Available Now (As of 11/29/2022*
  • Module 7: CAR T Cell and Cellular Therapy
  • Module 8: Implementing Cancer Immunotherapy in Clinical Practice


        To note, if you have previously completed the modules individually or are in the process of doing so, and are eligible to take the final assessment, please reach out to education@sitcancer.org to receive the final assessment exam.

          Certificate

          CP1.png

          SITC Graduate in Cancer Immunotherapy / SITC-G




          Non-certificate Track
          For learners that do not qualify for the SITC-G certificate, SITC welcomes you to take each modules to further your immunology/immunotherapy education. Learners are able to earn CME, CNE, CPE and MOC credit (as available in each module). Each module is available individually and the pricing is as follows:

          Individual Module Pricing:

          SITC Member Price: $25.00
          Non-Member Price: $31.25

          • Module 1: Basic Immunology Concepts, Updated Version Available Now (As of 10/14/2022*
            • This course, Module 1: Basic Immunology Concepts,will cover some of the key immunology needed to understand the rest of the certificate program.
          • Module 2: Basic Cancer Immunotherapy ConceptsUpdated Version Available Now (As of 11/14/2022*
            • This course, Module 2: Basic Cancer Immunotherapy Concepts, will cover the biological foundation of cancer immunotherapy, applying the basic immunology you learned in the last module to help lay the foundation for future topics in this program.
          • Module 3: Immune Checkpoint BlockadeUpdated Version Available Now (As of 03/20/2023*)
            • This course, Module 3: Immune Checkpoint Blockade, will cover the biological foundation of immune checkpoint blockade therapies as well as diving into their clinical use.
          • Module 6: Oncolytic Viruses and Intralesional TherapyUpdated Version Available Now (As of 11/29/2022*
            • This course, Module 6: Oncolytic Viruses and Intralesional Therapy, will cover the biological foundation and clinical implementation of intratumoral therapies and oncolytic viruses. 
            • This activity does not offer continuing education credit.
          • Module 7: CAR T Cell and Cellular Therapy
            • This course, Module 7: CAR T Cell and Cellular Therapy, will cover the mechanisms and clinical administration of cellular therapies for cancer, including an emphasis on adverse event management.
          • Module 8: Implementing Cancer Immunotherapy in Clinical Practice
            • This course, Module 8: Implementing Cancer Immunotherapy in Clinical Practice, will cover the practical aspects of instituting immunotherapy treatments in a clinical practice, such as education considerations, value-based care, and access to patient and provider resources.

          Target Audiences

          The primary target audience for the program is treating physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate will also be available to practicing, licensed NPs, PAs, and PharmDs (or RPh degree holders involved in direct clinical services), or global equivalent. The courses will be available to those who are not practicing clinicians, but they will not be eligible to earn the certificate.

          Requirements

          The requirements to earn the certificate include:

          • Must be a treating physician (U.S. licensed MD / DO or global equivalent), or a practicing licensed NP, PA, PharmD or RPh degree holder involved in direct clinical services, or global equivalent
          • Complete the coursework (all eight modules)
            • anticipated to be approximately 1 hour each, for a total of 8 hours
          • Pass all end-of-module assessments
          • Successfully complete a comprehensive exam covering all modules

          Certificate Term

          The certificate term is two years. Then, to earn a current certificate, which allows one to continue to use the SITC-G designation, an individual will need to take and pass updated coursework and assessments. If one misses the deadline for reissuance, he or she will need to retake and pass the full program.


          Learner Notification

          CLICK HERE



          Certificate Program Task Force


          CHAIR

          Robert L. Ferris, MD, PhD
          University of Pittsburgh Medical Center Hillman Cancer Center

          Members

          Leisha Emens, MD, PhD –
          University of Pittsburgh Medical Center Hillman Cancer Center
          Umar Farooq, MD – University of Iowa
          Silvia Formenti, MD – Weill Cornell Medicine
          Sigrun Hallmeyer, MD – Advocate Medical Group
          Howard Kaufman, MD, FACS –
          Ankyra Therapeutics/Massachusetts General Hospital
          Jose Lutzky, MD, FACP – University of Miami Sylvester Cancer Center
          George Weiner, MD – University of Iowa

          Requirements

          The requirements to earn the certificate include:
          • Complete the coursework (all eight modules)—anticipated to be approximately 1.5 hours each for a total of 12–16 hours
          • Pass all end-of-module assessments 
          • Successfully complete a comprehensive exam covering all modules